Thrive Earlier Detection Funding & Investors
Cambridge, MA
A cancer diagnosis is something no one wants to hear. Too often, cancer is detected late, once it has spread and treatment options are limited. But cancer can be more effectively treated with an intent to cure if caught in the earlier stages. At Thrive, an Exact Sciences Company, our goal is to transform this outlook: to catch cancer earlier, including several with no screening options today, to improve patient outcomes. We are developing a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.
thrivedetect.comTotal Amount Raised: $367,000,000
Thrive Earlier Detection Funding Rounds
Series B
$257,000,000
Series B Investors
Casdin CapitalSection 32Intermountain VenturesBain Capital Life SciencesRock Springs CapitalMoore Strategic VenturesBrown AdvisoryPerceptive AdvisorsT. Rowe PriceDriehaus Capital ManagementJanus Henderson InvestorsLux CapitalSands Capital ManagementInvus GroupThird Rock VenturesThe Blue Venture FundGamma3Camden PartnersCowin VentureBiomatics Capital PartnersExact SciencesSeries A
$110,000,000
Series A Investors
Third Rock VenturesBiomatics Capital PartnersThe Blue Venture FundSection 32Invus GroupCasdin CapitalCamden PartnersGamma3Exact SciencesCowin Venture